Joten M Tablet PR is a combination oral antidiabetic medication containing Metformin 500 mg and Teneligliptin 20 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone levels, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner. The extended-release formulation of Joten M Tablet PR allows for sustained plasma concentration, improving patient compliance and reducing gastrointestinal side effects commonly associated with metformin. This combination therapy is particularly beneficial for patients inadequately controlled on metformin monotherapy or those requiring dual mechanisms to achieve optimal glycemic targets. Joten M Tablet PR should be used as an adjunct to diet and exercise to improve glycemic control. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of pancreatitis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia (especially when combined with other antidiabetics), and rare cases of lactic acidosis. Regular monitoring of blood glucose, renal function, and overall metabolic status is recommended during therapy.